[Lutetium-177]Lu-PSMA-617 Delays Quality-of-Life Decline, Pain Progression, and Symptomatic Skeletal Events in PSMA-Positive mCRPC: In-depth PSMAfore Analysis

Highlights

– In the phase 3 PSMAfore trial, [177Lu]Lu-PSMA-617 delayed deterioration in patient-reported health-related quality of life (FACT-P and EQ-5D-5L) and pain (BPI-SF) versus a change in androgen receptor pathway inhibitor (ARPI) in taxane‑naive, PSMA PET–positive metastatic castration‑resistant prostate cancer (mCRPC).

– Median time to FACT-P deterioration was 7.46 months with [177Lu]Lu-PSMA-617 versus 4.27 months with ARPI change (HR 0.61, 95% CI 0.50–0.75).